POXEL S.A. Company Profile

00:49 EDT 20th August 2018 | BioPortfolio

News Articles [36 Associated News Articles listed on BioPortfolio]

Roivant, Poxel to develop and commercialise imeglimin in US, Europe and additional countries

Roivant Sciences and Poxel have signed a strategic development and license agreement for imeglimin, an investigational oral therapy which has been developed by Poxel for the potential treatment of typ...

Roivant, Poxel to develop type 2 diabetes drug

Roivant Sciences and Poxel will develop globally Poxel's imeglimin in all but 13 Asian nations in a deal that could generate  -More- 

Roivant to Codevelop Poxel's T2D Candidate Imeglimin in Up-to-$650M Partnership

Roivant Sciences will partner with Poxel to co-develop its Phase III-ready lead candidate, the type 2 diabetes treatment imeglimin, in the U.S., Europe, and elsewhere in the world except 13 Asian nati...

Roivant gets rights to Poxel's imeglimin worldwide except in certain Asian countries

Poxel SA licensed Roivant Sciences GMBH rights to develop and commercialize its Type II diabetes compound imeglimin in the US, Europe, and all other countries except certain Asian territories where Po...

Poxel completes enrolment in TIMES 1 trial

Poxel has completed patient enrolment for the TIMES 1 trial in Japan to investigate the use of Imeglimin for the...Read More... The post Poxel completes enrolment in TIMES 1 trial appeared first on Dr...

Poxel reports positive results from PXL770 phase 1b MAD trial and drug─drug interaction study

POXEL SA, a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non─alcoholic steatohepatitis (NASH), has announced f...

Roivant signs $600m licensing deal with Poxel

Roivant Sciences has announced that it has entered into a licensing partnership with Poxel to develop and commercialise the latter’s experimental drug imeglimin for a range of metabolic disorders in...

Roivant And Poxel Sign Agreement On Development Of Diabetes Therapy

NewsRoivant will be responsible for development and commercialization costs and Poxel will contribute $25 million to the development program. The parties will decide on a potential co-promotion prior ...

Drugs and Medications [0 Results]


PubMed Articles [0 Results]


Clinical Trials [1 Associated Clinical Trials listed on BioPortfolio]

Safety, Tolerability and PK of PXL770 in Healthy Male Subjects

PXL770 is a direct activator of 5' adenosine monophosphate-activated protein kinase (AMPK) being developed by Poxel S.A. for the treatment of type 2 diabetes mellitus (T2DM). In Part A of ...

Companies [2 Associated Companies listed on BioPortfolio]

Poxel SAS

Poxel is a new RIPCO that aims to advance promising assets for cardio-metabolic diseases from Research to Phase 2 Clinical Proof of Concept, before out licensing projects to pharmaceutical compani...


More Information about "POXEL S.A." on BioPortfolio

We have published hundreds of POXEL S.A. news stories on BioPortfolio along with dozens of POXEL S.A. Clinical Trials and PubMed Articles about POXEL S.A. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of POXEL S.A. Companies in our database. You can also find out about relevant POXEL S.A. Drugs and Medications on this site too.

Quick Search


Corporate Database Quicklinks

Searches Linking to this Company Record